EB virus-positive tumors are inhibited by rBCG expressing hGM-CSF and LMP2A

• Main Authors: Yingchun Yan (Author), Qing-Jie Xue (Author), Ang Liu (Author), Hui Wang (Author), Honghua Zhang (Author), Shuang Wang (Author), Longyu Zhao (Author), Yunqing Li (Author), Xiuzhen Li (Author), Yuanyuan Yang (Author), Ting Chen (Author), Shigen Li (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

For the development of safe and effective EBV (Epstein-Barr virus) vaccines, the Ag85A signal peptide from M. tuberculosis H37Rv was used to construct a recombinant secretory BCG (Bacillus Chalmette-Guérin) plasmid. The Ag85A gene, fused to the EBV LMP2A (latent membrane protein) and hGM-CSF (human granulocyte/macrophage colony-stimulating factor) genes, was inserted into the pMV261 vector (secretory BCG plasmid). The expression levels of the hGM-CSF and LMP2A proteins in rBCG (recombinant BCG) were measured by Western blot analysis. Humoral immunity, cellular immunity, and antitumor effects were determined by a series of experiments. The recombinant pMVGCA plasmid effectively expressed GCA (hGM-CSF and LMP2A fusion protein) in BCG after transformation, and the rBCG proteins were recognized by antibodies against hGM-CSF and LMP2A. Six weeks after immunization, the maximum dose of rBCG resulted in antibody titers of 1:19,800 (hGM-CSF antibody) and 1:21,800 (LMP2A antibody). When the effector:target ratio was 40:1, specific lysis was maximal and approximately two times stronger than that in mice immunized with the control. Tumorigenicity was lower in the rBCG treatment group, with a tumor inhibition rate of 0.81 ± 0.09 compared with the control groups. EB virus-positive tumors are inhibited by rBCG expressing an hGM-CSF and LMP2A fusion protein.

Item Description

2164-5515
2164-554X
10.1080/21645515.2019.1670593